STAAR Surgical (STAA) Total Debt to Capital

The total debt-to-equity ratio demonstrates the resilience of STAAR Surgical Company (STAA) during its expansion in Asia and increasing margins. STAAR Surgical Company (STAA) creates premium implants from patented Collamer as an alternative to laser surgery. The safety of microsurgery is ensured by high-cost air delivery in specialized containers. The value of 0.10 corresponds to the current metric, helping investors balance risk and return through an analysis of the business's debt load.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to owned assets, determining the business's financial leverage. For STAAR Surgical Company (STAA), with its patent monopoly on ICL lenses, a low debt load confirms the high self-sufficiency of the model. By analyzing the company's financial dependency trends, an investor can see the actual level of debt burden. This allows for an assessment of default risk during market fluctuations. A stable balance sheet confirms high capital resilience.